OTC Switch Public Health Arguments Tougher In Light Of FDA Stance
This article was originally published in The Tan Sheet
Executive Summary
Public health arguments supporting OTC switches for chronic indications become more difficult in light of FDA's refusal to consider economic implications for switching second-generation antihistamines, a J&J/Merck rep said June 11.
You may also be interested in...
FDA Forced OTC Switch Process Ambiguities Revealed At Subcmte. Hearing
FDA does not have an established procedure in place to prevent the disclosure of protected trade secrets in the event of a forced Rx-to-OTC switch, Center for Drug Evaluation & Research Director Janet Woodcock, MD, told a House panel June 13.
Chronic Condition OTC Mass Marketing Ineffective - Consultant
OTC switches of chronic condition drugs will necessitate a move away from the traditional mass marketing mindset to more targeted promotional approaches, NCI Consulting President Susan Lavine Coleman said at an Institute for International Research forum in New York June 11.
Switch Petitions Must Come From NDA Holders, CHPA Says
Drug manufacturers, with the guidance of FDA, are the only qualified parties to gather the data necessary to establish that a drug can be safely used without a prescription, the Consumer Healthcare Products Association asserts.